Encorafenib plus cetuximab with or without binimetinib for BRAF V600E-mutant metastatic colorectal cancer: Quality-of-life results from a randomized, three-arm, phase III study versus the choice of either irinotecan or FOLFIRI plus cetuximab (BEACON CRC) Meeting Abstract
| Authors: | Kopetz, S.; Grothey, A.; Van Cutsem, E.; Yaeger, R.; Wasan, H. S.; Yoshino, T.; Desai, J.; Ciardiello, F.; Loupakis, F.; Hong, Y. S.; Steeghs, N.; Guren, T. K.; Arkenau, H. T.; Garcia-Alfonso, P.; Gollerkeri, A.; Maharry, K.; Christy-Bittel, J.; Keir, C. H.; Pickard, M. D.; Tabernero, J. |
| Abstract Title: | Encorafenib plus cetuximab with or without binimetinib for BRAF V600E-mutant metastatic colorectal cancer: Quality-of-life results from a randomized, three-arm, phase III study versus the choice of either irinotecan or FOLFIRI plus cetuximab (BEACON CRC) |
| Meeting Title: | 2020 Gastrointestinal Cancers Symposium |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 38 |
| Issue: | 4 Suppl. |
| Meeting Dates: | 2020 Jan 23-25 |
| Meeting Location: | San Francisco, CA |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2020-02-01 |
| Language: | English |
| ACCESSION: | WOS:000530922700009 |
| PROVIDER: | wos |
| DOI: | 10.1200/JCO.2020.38.4_suppl.8 |
| Notes: | Meeting Abstract: 8 -- Source: Wos |
